1h Free Analyst Time
The retinal drugs market is forecasted to grow by USD 9.43 billion during 2024-2029, accelerating at a CAGR of 7.1% during the forecast period. The report on the retinal drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rise in prevalence of retinal diseases, emergence of advanced diagnostic tools, and patient assistance programs.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
The retinal drugs market is segmented as below:
By Distribution Channel
- Hospital pharmacy
- Retail pharmacy
- Online pharmacy
By Indication
- Macular degeneration
- Diabetic eye disease
- Others
By Drug Class
- VEGF-A antagonist
- TNF-A inhibitor
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the retinal drugs market covers the following areas:
- Retinal Drugs Market sizing
- Retinal Drugs Market forecast
- Retinal Drugs Market industry analysis
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Analysis
3 Market Landscape
4 Market Sizing
5 Historic Market Size
6 Qualitative Analysis
7 Five Forces Analysis
8 Market Segmentation by Distribution Channel
9 Market Segmentation by Indication
10 Market Segmentation by Drug Class
11 Customer Landscape
12 Geographic Landscape
13 Drivers, Challenges, and Opportunity/Restraints
14 Competitive Landscape
15 Competitive Analysis
16 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global retinal drugs market: AbbVie Inc., Alcon Inc., Alimera Sciences Inc., Bausch Health Companies Inc., Bayer AG, Bristol Myers Squibb Co., F. Hoffmann La Roche Ltd., Johnson and Johnson Services Inc., Kubota Corp., MeiraGTx Holdings Plc., Novartis AG, Ocular Therapeutix Inc, Oxurion N, Pfizer Inc., Regeneron Pharmaceuticals Inc., REGENXBIO Inc, Sanofi SA, Santen Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., and Visufarma.Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is development of innovative therapies."
According to the report, one of the major drivers for this market is the rise in prevalence of retinal diseases.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Alcon Inc.
- Alimera Sciences Inc.
- Bausch Health Companies Inc.
- Bayer AG
- Bristol Myers Squibb Co.
- F. Hoffmann La Roche Ltd.
- Johnson and Johnson Services Inc.
- Kubota Corp.
- MeiraGTx Holdings Plc.
- Novartis AG
- Ocular Therapeutix Inc
- Oxurion N
- Pfizer Inc.
- Regeneron Pharmaceuticals Inc.
- REGENXBIO Inc
- Sanofi SA
- Santen Pharmaceutical Co. Ltd.
- Teva Pharmaceutical Industries Ltd.
- Visufarma
